Anti-tumor immunity of newcastle disease virus hn protein is influenced by differential subcellular targeting

Chinese Journal of Lung Cancer

Volumn 13, Issue 8, 2010, Pages 773-776

  Wang, Kaibing ^a   Sui, Hong ^a   Li, Lejing ^a   Li, Xi ^b   Wang, Lei ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b Harbin Veterinary Research Institute   (China)

Author keywords

Anti tumor immunity; Cellular localization; Cytotoxic T lymphocyte; Hemagglutinin neuraminidase (HN) protein

Indexed keywords

CYTOPLASM PROTEIN; DNA; HN PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER MODEL; CELL ACTIVITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VIVO STUDY; LUNG CANCER; LYMPHOCYTE PROLIFERATION; MOUSE; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; TUMOR IMMUNITY;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; HN PROTEIN; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEWCASTLE DISEASE VIRUS; PROTEIN TRANSPORT; T-LYMPHOCYTES, CYTOTOXIC; VIRAL PROTEINS;

EID: 78049402337     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: 10.3779/j.issn.1009-3419.2010.08.04     Document Type: Article

References (14)

1. Heise C, Hermiston T, Johnson L, et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med, 2000, 6(10): 1134-1139.
2. Khuri KR, Nemunaitis J, Ganly I, et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorauracil in patients with recurrent head and neck cancer. Nat Med, 2000, 6(8): 879-885. (Pubitemid 30644745)
3. Nakano K, Todo T, Chijiiwa K, et al. Therapeutic efficacy of G207, a conditionally replicating herpes simplex virus type 1 mutant, for gallbladder carcinoma in immunocompetent hamsters. Mol Ther, 2001, 3(4): 431-437. (Pubitemid 32509836)
4. Stojdl DF, Lichty B, Knowles S, et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med, 2000, 6(7): 821-825.
5. Yu DC, Chen Y, Seng M, et al. The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. Cancer Res, 1999, 59(17): 4200-4203. (Pubitemid 29418725)
6. Fu F, Liu CY, Gao R, et al. Anti-tumor effects of NDV D90 against tumor cells of A549 in vitro. Chin J Prev Veter Med, 2008, 30(4): 179-182, 189.
7. Donahue JM, Mullen JT, Tanabe KK. Viral oncolysis. Surg Oncol Clin N Am, 2002, 11(3): 661-680.
8. Wei L, Dai JX, Sun SH. Construction of Newcastle disease virus hemagglutinin-neuraminidase (HN) gene and its antitumor immune response effects. Academic J Second Mil Med Univer, 2000, 21(6): 515-518.
9. He ZJ, Wang KB, Sui H, et al. The antitumor effect of newcastle disease virus HN protein on A549 in vitro targeting to different subcellular compartment. J Harbin Med Univer, 2010, 44(4): 292-295.
10. Sui H, Li X, Zhang YX, et al. Construction of the expression recombinant plasmid containing Newcastle disease virus HN targeting to different cellular compartments. Int J Immunol, 2009, 32(4): 258-262.
11. Grzelinski M, Steinberg F, Martens T, et al. Enhanced antitumorigenic effects in glioblastoma on double targeting of pleiotrophin and its receptor ALK. Neoplasia, 2009, 11(2): 145-156.
12. Hegde S, Niederkorn JY. The role of cytotoxic T lymphocytes in corneal allograft rejection. Invest Ophthalmol Visual Sci, 2000, 41(11): 3341-3347.
13. Bian H, Fournier P, Moormann R, et al. Selective gene transfer in vitro to tumor cells via recombinant Newcastle disease virus. Cancer Gene Ther, 2005, 12(3): 295-303.
14. Janke M, Peeters B, de Leeuw O, et al. Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy. Gene Ther, 2007, 14(23): 1639-1649. (Pubitemid 350143189)